Parts of this work were presented in poster format at the 2nd International Conference on Psychogenic Movement Disorders and Other Conversion Disorders, Washington, D.C., April 2009.
Article first published online: 19 OCT 2009
Copyright © 2009 Wiley-Liss, Inc.
American Journal of Medical Genetics Part A
Volume 149A, Issue 11, pages 2501–2506, November 2009
How to Cite
Seritan, A. L., Schneider, A., Olichney, J. M., Leehey, M. A., Akins, R. S. and Hagerman, R. J. (2009), Conversion disorder in women with the FMR1 premutation. Am. J. Med. Genet., 149A: 2501–2506. doi: 10.1002/ajmg.a.33054
How to cite this article: Seritan AL, Schneider A, Olichney JM, Leehey MA, Akins RS, Hagerman RJ. 2009. Conversion disorder in women with the FMR1 premutation. Am J Med Genet Part A 149A:2501–2506.
- Issue published online: 28 OCT 2009
- Article first published online: 19 OCT 2009
- Manuscript Accepted: 7 JUN 2009
- Manuscript Received: 15 APR 2009
- National Institutes of Health. Grant Numbers: DE19583, AG032115, AG032119, HD036071, HD02274, AG18442
- State of California Department of Public Health (Alzheimer's Disease Program)
- psychogenic nonepileptic seizures;
- FMR1 premutation
Women with fragile X mental retardation (FMR1) gene premutations (55–200 CGG repeats) were until recently believed to be unaffected. It is now known that up to 8% of older female FMR1 premutation carriers develop fragile X-associated tremor/ataxia syndrome (FXTAS). Female carriers may also develop primary ovarian insufficiency, thyroid disease, hypertension, seizures, peripheral neuropathy, and fibromyalgia. We present a 60-year-old woman with FMR1 premutation who had depression, anxiety, and conversion disorder with seizures. The FMR1 premutation with its associated mRNA toxicity is postulated as an underlying neurobiological mechanism of conversion symptoms, through functional and structural neural dysconnectivity. © 2009 Wiley-Liss, Inc.